A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2, and CYP2C19*3 alleles involving time-resolved fluorometry

被引:11
|
作者
Bathum, L
Hansen, TS
Horder, M
Brosen, K
机构
[1] Odense Univ Hosp, Dept Clin Biochem, DK-5000 Odense C, Denmark
[2] Odense Univ, Dept Clin Pharmacol, DK-5230 Odense, Denmark
关键词
CYP2C19; genotyping; genetic polymorphism;
D O I
10.1097/00007691-199802000-00001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
CYP2C19 (S-mephenytoin hydroxylase) is a polymorphically expressed enzyme. Currently, two defective alleles are known-CYP2C19*2 and CYP2C19*3. The authors have developed an oligonucleotide ligation assay to detect these two alleles. This assay combines the hybridization of one common, biotinylated capture probe and two allele-specific probes to the target DNA, with the ability of a DNA ligase to distinguish mismatched nucleotides. The probes are only ligated if they are base paired correctly to the target strand. The biotin is bound to streptavidin, and all DNA not covalently bound to the biotin-labeled capture probe, is removed in a washing procedure. The allele-specific probes are labeled with either europium or samarium, and their emission can be measured simultaneously. The ratio between the emission separates the genotypes. This method was applied on DNA from 19 whites and 21 Vietnamese living in Denmark. All genotypes determined by the assay were consistent with the results from restriction enzyme cleavage. There were 12 poor metabolizers; 10 homozygous CYP2C19*2/CYP2C19*2, one heterozygous CYP2C19*2/CYP2C19*3, and one heterozygous CYP2C19*1/CYP2C19*2. The authors conclude that this assay is well-suited for a high throughput of samples in a routine laboratory. The finding of an apparently heterozygous CYP2C19*1/CYP2C19*2 poor metabolizer, confirms that there are still unknown mutations in CYP2C19.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [31] In Vitro Functional Characterisation of Cytochrome P450 (CYP) 2C19 Allelic Variants CYP2C19*23 and CYP2C19*24
    Pui Shen Lau
    Kenny Voon Gah Leong
    Chin Eng Ong
    Amelia Nathania Hui Min Dong
    Yan Pan
    Biochemical Genetics, 2017, 55 : 48 - 62
  • [32] Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity Role of CYP2D6 and CYP2C19 in longevityRole of CYP2D6 and CYP2C19 in longevity
    L. Bathum
    K. Andersen-Ranberg
    J. Boldsen
    K. Brøsen
    B. Jeune
    European Journal of Clinical Pharmacology, 1998, 54 : 427 - 430
  • [33] Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole
    Klomp, Sylvia D.
    Veringa, Anette
    Alffenaar, Jan-Willem C.
    de Boer, Mark G. J.
    Span, Lambert F. R.
    Guchelaar, Henk-Jan
    Swen, Jesse J.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (07):
  • [34] Inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of the CYP2C19*17 allele
    Pedersen, Rasmus S.
    Noehr-Jensen, Lene
    Brosen, Kim
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2013, 40 (10): : 683 - 688
  • [35] Linkage of mutant alleles of CYP2C18 and CYP2C19 in a Japanese population
    Kubota, T
    Hibi, N
    Chiba, K
    BIOCHEMICAL PHARMACOLOGY, 1998, 55 (12) : 2039 - 2042
  • [36] Detection of CYP2C19 alleles*1,*2 and*3 by multiplex polymerase chain reaction
    Griese, EU
    Läpple, F
    Eichelbaum, M
    PHARMACOGENETICS, 1999, 9 (03): : 389 - 391
  • [37] INDIVIDUAL DIFFERENCES OF CYP2C19 mRNA EXPRESSION AND CYP2C19 GENETIC POLYMORPHISM IN THE SMALL INTESTINE OF JAPANESE
    Hayashi, Mikihilo
    Kinoshita, Yoichi
    Takenoshita, Sachiko
    Kurnai, Toshio
    Matsumoto, Naoki
    Kobayashi, Shinichi
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1106 - 1106
  • [38] Omeprazole-induced acute interstitial nephritis is not related to CYP2C19 genotype or CYP2C19 phenotype
    Helsby, Nuala A.
    Lo, Wing-Yee
    Simpson, Ian J.
    Voss, David M.
    Logan, Kaye E.
    Searle, Martin
    Schollum, John B. W.
    de Zoysa, Janak R.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (05) : 516 - 519
  • [39] Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & Tobago
    Daniele Jones
    Shana Persad-Ramdeensingh
    Sheherazade Crystal Abrahim
    Naveen Seecheran
    Rajini Rani Haraksingh
    Cardiology and Therapy, 2024, 13 : 191 - 203
  • [40] A synergic effect between CYP2C19∗2, CYP2C19∗3 loss-of-function and CYP2C19∗17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients
    Hassani Idrissi H.
    Hmimech W.
    Khorb N.E.
    Akoudad H.
    Habbal R.
    Nadifi S.
    BMC Research Notes, 11 (1)